SUNDAY, MARCH 3
Arrival and Registration

MONDAY, MARCH 4
Welcome and Keynote Address
Arun J. Sanyal, Virginia Commonwealth University Medical Center, USA
MASH and Fibrosis: What have we Learned from Clinical Trials?

The Origin of the Nile: What is the Culprit of MASH?
Mohammed Eslam, University of Sydney, Australia
Nutritional, Non-Alcoholic or Metabolic associated Fatty Liver Disease?

Amalia Gastaldelli, Institute of Clinical Physiology, Italy
Worsening of Metabolic Fluxes: From Hepatic Steatosis to MASH

Silvia C. Sookoian, CONICET. Universidad Maimonides, Argentina
Epigenetic Changes in the Progression from MASH to Fibrosis

Sofia Forslund, Max Delbrück Center, Germany
Towards Personalized Nutrition in Steatotic Liver Disease

Workshop 1
Short Talks Chosen from Abstracts

Steatotic Liver Disease: Multiple Phenotypes or Different Diseases?
Vincent WS Wong, Chinese University of Hong Kong, Hong Kong
Lean NAFLD: Molecular Mechanisms of MASH and Fibrosis

Julia Kozlakina, University of Texas Southwestern Medical Center, USA
Molecular Basis of Ethnic Differences in MASH and Fibrosis

Päivi Pajukanta, David Geffen School of Medicine at UCLA, USA
MASH and Fibrosis: From Molecular Phenotypes to Precision Therapeutics

Lewis R. Roberts, Mayo Clinic, USA
Cirrhotic and Noncirrhotic: Mechanisms of Hepatocellular Carcinoma in SLD

Short Talks Chosen from Abstracts

Poster Session 1

TUESDAY, MARCH 5
Preclinical Model of MASH Clinical Trials
Mitchell A. Lazar, Perelman School of Medicine, University of Pennsylvania, USA
Human Stem Cells/Organoids for Precision Medicine in Steatotic Liver Disease

Peter Olinga, University of Groningen, Netherlands
Precision Slice Cut as a Preclinical Model of MASH

Jennifer L. Estall, Institut de Recherches Cliniques de Montréal, Canada
Modeling MASH in Mice: Overcoming Problems in Translation

Short Talks Chosen from Abstracts

Health Equity Forum

Career Roundtable

Current Status and Future of Endpoints to Assess Efficacy in Clinical Trials
Alina M. Allen, Mayo Clinic, USA
Identifying Populations at Risk for Liver Events – is MASH with Fibrosis by Histology the Only Way?

Michael Charlton, University of Chicago, USA
Is Regression of Fibrosis the Only Surrogate for Outcomes Benefit?

Manal F. Abdelmalek, Mayo Clinic, USA
Assessing Response to Drug Treatment Beyond Liver Biopsy

Short Talks Chosen from Abstracts

Poster Session 2

WEDNESDAY, MARCH 6
Genetic Insights into MASH, Fibrosis and Hepatocellular Carcinoma
Stefano Romeo, University of Gothenburg, Sweden
Human Genetics of Steatotic Liver Disease: What Have We Learned So Far?

Luca Vittorio Carlo Valenti, University of Milan, Italy
PNPLA3, Estrogens and SLD Progression in Women

Luca Lotta, Regeneron Pharmaceuticals Inc., USA
Human Genetics of Liver Disease and Implications for Therapeutic Development

Short Talks Chosen from Abstracts

Workshop 2
Short Talks Chosen from Abstracts

Opportunities and Challenges of Precision Medicine in Steatotic Liver Disease
Heather Hsu, Inipharm, USA
Inhibition of HSD17B13 Decreases Fibrosis and the MASH Phenotype

Gregory Tesz, Pfizer, USA
Targeting PNPLA3 148M to Treat MASH and Fibrosis

Shuang (Sammi) Wang, Icahn School of Medicine at Mount Sinai, USA
Hepatic Stellate Cell Plasticity and Maladaptive Fibrogenic Memory in CLD

Short Talks Chosen from Abstracts

Meeting Wrap-Up: Outcomes and Future Directions (Organizers)

THURSDAY, MARCH 7
Departure